Regencell Bioscience Plunges 15.15% Amid Bearish Technicals

On June 20, 2025, Regencell Bioscience experienced a significant drop of 15.15% in pre-market trading, reflecting the ongoing volatility and instability in the stock's performance.

Regencell Bioscience has been identified as a promising growth stock, with its share price skyrocketing by 575% this year. However, the recent volatility has led to significant declines, with the stock experiencing extreme bearish momentum and critical support breaks.

The technical landscape for Regencell Bioscience is challenging, with multiple indicators pointing to a bearish trend. The stock has formed highly bearish candlestick patterns, and the moving averages depict a severe downtrend. The MACD and KDJ indicators are firmly entrenched in bearish territory, while Bollinger Bands reflect heightened volatility and bearish pressure.

Volume analysis validates the bearish momentum, with significant selling conviction during the recent declines. The Relative Strength Index (RSI) confirms a deeply oversold condition, but this does not inherently signal a reversal in the current trend. Fibonacci retracement levels highlight deep retracement levels, with substantial resistance zones emerging at key levels.

Overall, Regencell Bioscience exhibits overwhelming technical bearishness across all analyzed indicators. The stock has entered a steep decline phase characterized by high volatility and persistent oversold readings without stabilization. While temporary relief rallies may occur, the technical structure severely undermines their sustainability absent a major catalyst. Downside targets potentially extend towards the $50-$30 range based on Fibonacci levels and historical support. Resistance is formidable, commencing near $78-$95. A significant base-building process appears necessary before any durable recovery can be contemplated.